Osteoprotegerin/RANKL system imbalance in active polyarticular‐onset juvenile idiopathic arthritis: a bone damage biomarker?

References

• Cassidy J. T. Juvenile rheumatoid arthritis. Textbook of pediatric rheumatology, J. T Cassidy, R. E Petty. W.B. Saunders Company, Philadelphia, PA 2001; 133–219, 4th edn
   Google Scholar
• Brewer E. J., Jr., Bass J., Baum J., Cassidy J. T., Fink C., Jacobs J., et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of Diagnostic and Therapeutic Criteria of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum 1997; 20: 195–9
   Google Scholar
• Ronchezel M. V., Hilario M. O., Goldenberg J., Lederman H. M., Faltin K., Jr., de Azevedo M. F., et al. Temporomandibular joint and mandibular growth alterations in patients with juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 1956–61
   PubMed Web of Science ®Google Scholar
• Adib N., Silman A., Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. Predictors of outcome in juvenile arthritis. Rheumatology 2005; 44: 1002–7
   PubMed Web of Science ®Google Scholar
• Vervoordeldonk M. J., Tak P. P. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002; 4: 208–17
   PubMedGoogle Scholar
• Levalampi T., Honkanen V., Lahdenne P., Nieminen R., Hakala M., Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007; 36: 189–93
   PubMed Web of Science ®Google Scholar
• Hofbauer L. C., Heufelder A. E. Role of receptor activator of nuclear factor‐kB ligand and osteoprotegerin in bone cell biology. J Mol Méd 2001; 79: 243–53
   PubMed Web of Science ®Google Scholar
• Bezerra M. C., Carvalho J. F., Prokopowitsch A. S., Pereira R. M. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005; 38: 161–70
   PubMed Web of Science ®Google Scholar
• Lerner U. H. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathologic bone resorption. Crit Rev Oral Biol Med 2004; 15: 64–81
   PubMedGoogle Scholar
• Teng Y. T., Nguyen H., Gao X., Kong Y. Y., Gorczynski M., Singh B., et al. Functional human T‐cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: 59–67
   PubMed Web of Science ®Google Scholar
• Pereira R. M., Corrente J. E., Chahade W. H., Yoshinari N. H. Evaluation by dual X‐ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. Clin Exp Rheumatol 1998; 16: 495–501
   PubMed Web of Science ®Google Scholar
• Reed M. H., Wilmot D. M. The radiology of juvenile rheumatoid arthritis. A review of the English language literature. J Rheumatol 1991; 18((Suppl 31))2–22
   Google Scholar
• Mason T., Reed A. M., Nelson A. M., Thomas K. B., Patton A., Hoffman A. D., et al. Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 2214–18
   PubMed Web of Science ®Google Scholar
• Kong Y. Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304–9
   PubMed Web of Science ®Google Scholar
• Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390–2
   PubMed Web of Science ®Google Scholar
• Lurati A., Pontikaki I., Teruzzi B., Desiati F., Gerloni V., Gattinara M., et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti‐tumor necrosis factor alpha agents. Arthritis Rheum 2006; 54: 1602–7
   PubMed Web of Science ®Google Scholar
• Almeida P. M., Wickerhauser H. Finding a better socio‐economic status classification system for Brazil. J Marketing Res 1988; 19: 240–50
   Google Scholar
• Tanner J. M., O'Keefe B. Age at menarche in Nigerian school girls, with a note on their heights and weights from age 12 to 19. Hum Biol 1962; 34: 187–96
   PubMed Web of Science ®Google Scholar
• van Rossum M. A. J., Zwinderman A. H., Boers M., Dijkmans B. A. C., van Soesbergen R. M., Fiselier T. J. W., et al. Radiologic features in juvenile idiopathic arthritis. Arthritis Rheum 2003; 48: 507–15
   PubMed Web of Science ®Google Scholar
• Steinbrocker O. Prognosis for employability in the major arthritides rheumatoid arthritis, osteoarthritis and gout. Pa Med 1969; 72: 82–5
   PubMedGoogle Scholar
• Brasil T. B., Ferriani V. P., Machado C. S. Health‐related quality of life survey about children and adolescents with juvenile idiopathic arthritis. J Pediatr (Rio J) 2003; 79: 373, author reply 374
   PubMedGoogle Scholar
• Bezerra M. C., Calomeni G. D., Caparbo V. F., Gebrim E. S., Rocha M. S., Pereira R. M. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology 2005; 44: 1503–6
   PubMed Web of Science ®Google Scholar
• Santiago R. A., Silva C. A., Caparbo V. F., Sallum A. M., Pereira R. M. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol 2008; 37: 40–7
   PubMed Web of Science ®Google Scholar
• Theill L. E., Boyle W. J., Penninger J. M. RANKL and RANK: T cells, bone loss and mammalian evolution. Annu Rev Immunol 2002; 20: 795–823
   PubMed Web of Science ®Google Scholar
• Walsh M. C., Choi X. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003; 14: 251–63
   PubMed Web of Science ®Google Scholar
• Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentation factor. Arthritis Rheum 2000; 43: 250–8
   PubMed Web of Science ®Google Scholar
• Romas E., Bakharevski O., Hards D. K., Kartsogiannis V., Quinn J. M., Ryan P. F., et al. Expression of osteoclast differentation factor at sites of bone erosion in collagen‐induced arthritis. Arthritis Rheum 2000; 43: 821–6
   PubMed Web of Science ®Google Scholar
• Stern A., Laughlin G. A., Bergstrom J., Barret‐Connor E. The sex‐specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007; 156: 555–62
   PubMed Web of Science ®Google Scholar
• Masi L., Simonini G., Piscitelli E., Del Monte F., Giani T., Cimaz R., et al. Osteoprotegerin (OPG)/RANK‐L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK‐L in bone injury?. J Rheumatol 2004; 31: 986–91
   PubMed Web of Science ®Google Scholar
• Kerschan‐Schindl K., Wendlova J., Kudlacek S., Gleiss A., Woloszczuk W., Pietschmann P. Serum levels of receptor activator of nuclear factor kappa B ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 2007, Dec 10 [Epub ahead of print]; DOI: 10.1055/s‐2007‐993142
   PubMed Web of Science ®Google Scholar
• Sarma P. K., Misra R., Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 2008; 27: 289–94
   PubMed Web of Science ®Google Scholar
• Pereira R. M., Delany A. M., Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001; 28: 484–90
   PubMed Web of Science ®Google Scholar
• Canalis E. Mechanism of glucocorticoid action in bone. Curr Osteoporos Rep 2005; 3: 98–102
   PubMedGoogle Scholar
• Boyle W. J., Simonet W. S., Lacey D. L. Osteoclast differentiation and activation. Nature 2003; 423: 337–42
   PubMed Web of Science ®Google Scholar
• Yilmaz M., Kendirli S. G., Altintas D., Bingol G., Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001; 20: 30–5
   PubMed Web of Science ®Google Scholar
• Kutukculer N., Caglayan S., Aydogdu F. Study of pro‐inflammatory (TNF‐alpha, IL‐1alpha, IL‐6) and T‐cell‐derived (IL‐2, IL‐4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998; 17: 288–92
   PubMed Web of Science ®Google Scholar
• Huang J. L., Kuo M. L., Hung I. J., Wu C. J., Ou L. H., Cheng J. H. Lowered IL‐4‐producing T cells and decreased IL‐4 secretion in peripheral blood from subjects with juvenile rheumatoid arthritis. Chang Gung Med J 2001; 24: 77–83
   PubMedGoogle Scholar
• Pettit A. R., Ji H., von Stechow D., Müller R., Goldring S. R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159: 1689–99
   PubMed Web of Science ®Google Scholar
• Zwerina J., Hayer S., Tohidast‐Akrad M., Bergmeister H., Redlich K., Feige U., et al. Single and combined inhibition of tumor necrosis factor, interleukin‐1, and RANKL pathways in tumor necrosis factor‐induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277–90
   PubMed Web of Science ®Google Scholar